Manufacturers should think twice before developing a self-administered biosimilar
Samsung Bioepis report says Humira has 97% of the adalimumab market almost a year after it lost exclusivity
Humira has nearly 100% of the U.S. adalimumab market despite the launch of nine biosimilars discounted by up to 86%, according to a report by Samsung Bioepis. AbbVie’s successful use of rebates to secure favorable formulary positioning could make manufacturers pause before committing the $100-$300 million McKinsey & Company estimates is needed to develop biosimilars that are reimbursed under the pharmacy benefit, where Medicare Part B’s parity coverage does not apply.
Published Jan. 18, the report by Samsung Bioepis Co. Ltd. gives an early read into the fortune of the nine FDA-approved adalimumab biosimilars. Their ability to impact one of the most durable and lucrative franchises in the history of medicine was widely seen as a biosimilar test case. ...